HealthMyne operates in the healthcare technology sector, specializing in quantitative imaging and radiomics to support oncology decision-making. The company provides a comprehensive platform that integrates multiple clinical decision support (CDS) workflow solutions, aimed at improving the efficiency and accuracy of cancer diagnosis and treatment. HealthMyne's software solutions are designed to serve multidisciplinary care teams, including radiologists, oncologists, and other healthcare professionals involved in cancer care. The platform offers features such as semi-automated tumor segmentation, incidental findings tracking, and radiomic analysis, which help in predicting survival outcomes and ensuring timely patient follow-up.

HealthMyne primarily targets healthcare institutions, research organizations, and clinical trial groups. The company operates in the global healthcare market, focusing on regions with advanced medical infrastructure. Its business model is based on a software-as-a-service (SaaS) approach, generating revenue through subscription fees for its platform and additional services.

The company's innovative approach in integrating radiomics into clinical workflows sets it apart from traditional imaging solutions. By providing actionable insights and enhancing the decision-making process, HealthMyne aims to improve patient outcomes and streamline oncology care.

Keywords: quantitative imaging, radiomics, oncology, clinical decision support, tumor segmentation, incidental findings, healthcare technology, multidisciplinary care, SaaS, patient outcomes.